Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

Doctor Edward Dwyer knows gout when he sees it ... Within the past few years a second agent, febuxostat, has become available and works in the exact same way. And finally an enzymatic protein ...

Gout is inflammatory arthritis that causes ... Examples include Benemid (probenecid), Zyloprim (allopurinol), and Uloric ...

A new drug called febuxostat has been found to reduce plasma levels of uric acid more effectively in Gout than the currently used drug allopurinol. If the results of the clinical trial are ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

1 In this study, 451 gout patients were randomized into either the dotinurad group or febuxostat group in a 1:1 ratio. The results of this study showed that the proportion of subjects with serum ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Addressable Gout Market Opportunity In North America ... An alternative XOI, Febuxostat, launched in the US in 2009 with the hope of treating allopurinol intolerant patients, however while ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...